An individualised risk-Adapted protocol of pre-and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation

Results of a phase II prospective trial

Andrew P Grigg, B. Butcher, B. Khodr, Ashish Bajel, Mark Hertzberg, S. Patil, A. B. D'Souza, Peter Ganly, P. Ebeling, E. Wong

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Bone loss occurs frequently following allogeneic haematopoietic stem cell transplantation (alloSCT). The Australasian Leukaemia and Lymphoma Group conducted a prospective phase II study of pretransplant zoledronic acid (ZA) and individualised post-Transplant ZA to prevent bone loss in alloSCT recipients. Patients received ZA 4 mg before conditioning. Administration of post-Transplant ZA from days 100 to 365 post alloSCT was determined by a risk-Adapted algorithm based on serial bone density assessments and glucocorticoid exposure. Of 82 patients enrolled, 70 were alive and without relapse at day 100. A single pretransplant dose of ZA prevented femoral neck bone loss at day 100 compared with baseline (mean change '2.6±4.6%). Using the risk-Adapted protocol, 42 patients received ZA between days 100 and 365 post alloSCT, and this minimised bone loss at day 365 compared with pretransplant levels (mean change '2.9±5.3%). Femoral neck bone loss was significantly reduced in ZA-Treated patients compared with historical untreated controls at days 100 and 365. This study demonstrates that a single dose of ZA pre-AlloSCT prevents femoral neck bone loss at day 100 post alloSCT, and that a risk-Adapted algorithm is able to guide ZA administration from days 100 to 365 post transplant and minimise further bone loss.

Original languageEnglish
Pages (from-to)1288-1293
Number of pages6
JournalBone Marrow Transplantation
Volume52
Issue number9
DOIs
Publication statusPublished - 1 Sep 2017

Cite this

Grigg, Andrew P ; Butcher, B. ; Khodr, B. ; Bajel, Ashish ; Hertzberg, Mark ; Patil, S. ; D'Souza, A. B. ; Ganly, Peter ; Ebeling, P. ; Wong, E. / An individualised risk-Adapted protocol of pre-and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation : Results of a phase II prospective trial. In: Bone Marrow Transplantation. 2017 ; Vol. 52, No. 9. pp. 1288-1293.
@article{8796bb63ecbb4c58ad996bf1ba21e133,
title = "An individualised risk-Adapted protocol of pre-and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: Results of a phase II prospective trial",
abstract = "Bone loss occurs frequently following allogeneic haematopoietic stem cell transplantation (alloSCT). The Australasian Leukaemia and Lymphoma Group conducted a prospective phase II study of pretransplant zoledronic acid (ZA) and individualised post-Transplant ZA to prevent bone loss in alloSCT recipients. Patients received ZA 4 mg before conditioning. Administration of post-Transplant ZA from days 100 to 365 post alloSCT was determined by a risk-Adapted algorithm based on serial bone density assessments and glucocorticoid exposure. Of 82 patients enrolled, 70 were alive and without relapse at day 100. A single pretransplant dose of ZA prevented femoral neck bone loss at day 100 compared with baseline (mean change '2.6±4.6{\%}). Using the risk-Adapted protocol, 42 patients received ZA between days 100 and 365 post alloSCT, and this minimised bone loss at day 365 compared with pretransplant levels (mean change '2.9±5.3{\%}). Femoral neck bone loss was significantly reduced in ZA-Treated patients compared with historical untreated controls at days 100 and 365. This study demonstrates that a single dose of ZA pre-AlloSCT prevents femoral neck bone loss at day 100 post alloSCT, and that a risk-Adapted algorithm is able to guide ZA administration from days 100 to 365 post transplant and minimise further bone loss.",
author = "Grigg, {Andrew P} and B. Butcher and B. Khodr and Ashish Bajel and Mark Hertzberg and S. Patil and D'Souza, {A. B.} and Peter Ganly and P. Ebeling and E. Wong",
year = "2017",
month = "9",
day = "1",
doi = "10.1038/bmt.2017.108",
language = "English",
volume = "52",
pages = "1288--1293",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

An individualised risk-Adapted protocol of pre-and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation : Results of a phase II prospective trial. / Grigg, Andrew P; Butcher, B.; Khodr, B.; Bajel, Ashish; Hertzberg, Mark; Patil, S.; D'Souza, A. B.; Ganly, Peter; Ebeling, P.; Wong, E.

In: Bone Marrow Transplantation, Vol. 52, No. 9, 01.09.2017, p. 1288-1293.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - An individualised risk-Adapted protocol of pre-and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation

T2 - Results of a phase II prospective trial

AU - Grigg, Andrew P

AU - Butcher, B.

AU - Khodr, B.

AU - Bajel, Ashish

AU - Hertzberg, Mark

AU - Patil, S.

AU - D'Souza, A. B.

AU - Ganly, Peter

AU - Ebeling, P.

AU - Wong, E.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Bone loss occurs frequently following allogeneic haematopoietic stem cell transplantation (alloSCT). The Australasian Leukaemia and Lymphoma Group conducted a prospective phase II study of pretransplant zoledronic acid (ZA) and individualised post-Transplant ZA to prevent bone loss in alloSCT recipients. Patients received ZA 4 mg before conditioning. Administration of post-Transplant ZA from days 100 to 365 post alloSCT was determined by a risk-Adapted algorithm based on serial bone density assessments and glucocorticoid exposure. Of 82 patients enrolled, 70 were alive and without relapse at day 100. A single pretransplant dose of ZA prevented femoral neck bone loss at day 100 compared with baseline (mean change '2.6±4.6%). Using the risk-Adapted protocol, 42 patients received ZA between days 100 and 365 post alloSCT, and this minimised bone loss at day 365 compared with pretransplant levels (mean change '2.9±5.3%). Femoral neck bone loss was significantly reduced in ZA-Treated patients compared with historical untreated controls at days 100 and 365. This study demonstrates that a single dose of ZA pre-AlloSCT prevents femoral neck bone loss at day 100 post alloSCT, and that a risk-Adapted algorithm is able to guide ZA administration from days 100 to 365 post transplant and minimise further bone loss.

AB - Bone loss occurs frequently following allogeneic haematopoietic stem cell transplantation (alloSCT). The Australasian Leukaemia and Lymphoma Group conducted a prospective phase II study of pretransplant zoledronic acid (ZA) and individualised post-Transplant ZA to prevent bone loss in alloSCT recipients. Patients received ZA 4 mg before conditioning. Administration of post-Transplant ZA from days 100 to 365 post alloSCT was determined by a risk-Adapted algorithm based on serial bone density assessments and glucocorticoid exposure. Of 82 patients enrolled, 70 were alive and without relapse at day 100. A single pretransplant dose of ZA prevented femoral neck bone loss at day 100 compared with baseline (mean change '2.6±4.6%). Using the risk-Adapted protocol, 42 patients received ZA between days 100 and 365 post alloSCT, and this minimised bone loss at day 365 compared with pretransplant levels (mean change '2.9±5.3%). Femoral neck bone loss was significantly reduced in ZA-Treated patients compared with historical untreated controls at days 100 and 365. This study demonstrates that a single dose of ZA pre-AlloSCT prevents femoral neck bone loss at day 100 post alloSCT, and that a risk-Adapted algorithm is able to guide ZA administration from days 100 to 365 post transplant and minimise further bone loss.

UR - http://www.scopus.com/inward/record.url?scp=85028840327&partnerID=8YFLogxK

U2 - 10.1038/bmt.2017.108

DO - 10.1038/bmt.2017.108

M3 - Article

VL - 52

SP - 1288

EP - 1293

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -